EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Oral enzyme therapy for maple syrup urine disease ( MSUD ) suppresses plasma leucine levels in intermediate MSUD mice and healthy nonhuman primates

Kristen Skvorak, Joyce Liu, Nikki Kruse, Roasa Mehmood, Subhamoy Das, Stephan Jenne, Chinping Chng, U Loi Lao, Da Duan, Jonathan Asfaha, Faye Du, Leann Teadt und 10 weitere

Journal of Inherited Metabolic Disease · 2023

DOI: 10.1002/jimd.12662 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2023. Verfasst von Kristen Skvorak und 21 weiteren Autor:innen. Beteiligte Einrichtung: Codexis, Inc., Redwood City, California, USA. Hauptthemen laut MEDLINE: Maple Syrup Urine Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Maple syrup urine disease (MSUD) is an inborn error of branched‐chain amino acid metabolism affecting several thousand individuals worldwide. MSUD patients have elevated levels of plasma leucine and its metabolic product α‐ketoisocaproate (KIC), which can lead to severe neurotoxicity, coma, and death. Patients must maintain a strict diet of protein restriction and medical formula, and periods of noncompliance or illness can lead to acute metabolic decompensation or cumulative neurological impairment. Given the lack of therapeutic options for MSUD patients, we sought to develop an oral enzyme therapy that can degrade leucine within the gastrointestinal tract prior to its systemic absorption and thus enable patients to maintain acceptable plasma leucine levels while broadening their access to natural protein. We identified a highly active leucine decarboxylase enzyme from Planctomycetaceae bacterium and used directed evolution to engineer the enzyme for stability to gastric and intestinal conditions. Following high‐throughput screening of over 12 000 enzyme variants over 9 iterative rounds of evolution, we identified a lead variant, LDCv10, which retains activity following simulated gastric or intestinal conditions in vitro. In intermediate MSUD mice or healthy nonhuman primates given a whey protein meal, oral treatment with LDCv10 suppressed the spike in plasma leucine and KIC and reduced the leucine area under the curve in a dose‐dependent manner. Reduction in plasma leucine correlated with decreased brain leucine levels following oral LDCv10 treatment. Collectively, these data support further development of LDCv10 as a potential new therapy for MSUD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Maple Syrup Urine DiseaseHumansMiceAnimalsLeucineAmino Acids, Branched-ChainProteinsEnzyme TherapyPrimates

Stichwörter der Autor:innen

branched-chain amino acid deficiencyenzyme engineeringenzyme replacement therapyinborn errors of metabolismleucine decarboxylasemaple syrup urine disease

Substanzen

LeucineAmino Acids, Branched-ChainProteins

Autor:innen und Institutionen

  • Codexis, Inc., Redwood City, California, USA.

ORCID-Profile: Adam P Silverman

Zitieren

APA

Skvorak, K., Liu, J., Kruse, N., Mehmood, R., Das, S., Jenne, S., Chng, C., Lao, U. L., Duan, D., Asfaha, J., Du, F., Teadt, L., Sero, A., Ching, C., Riggins, J., Pope, L., Yan, P., Mashiana, H., Ismaili, M. H. A., …, & Silverman, A. P. (2023). Oral enzyme therapy for maple syrup urine disease ( MSUD ) suppresses plasma leucine levels in intermediate MSUD mice and healthy nonhuman primates. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12662

Vancouver

Skvorak K, Liu J, Kruse N, Mehmood R, Das S, Jenne S, et al. Oral enzyme therapy for maple syrup urine disease ( MSUD ) suppresses plasma leucine levels in intermediate MSUD mice and healthy nonhuman primates. Journal of Inherited Metabolic Disease. 2023. doi:10.1002/jimd.12662

BibTeX
@article{Skvorak2023,
  author = {Skvorak, Kristen and Liu, Joyce and Kruse, Nikki and Mehmood, Roasa and Das, Subhamoy and Jenne, Stephan and Chng, Chinping and Lao, U Loi and Duan, Da and Asfaha, Jonathan and Du, Faye and Teadt, Leann and Sero, Antionette and Ching, Charlene and Riggins, James and Pope, Lianne and Yan, Ping and Mashiana, Harminder and Ismaili, Moulay Hicham Alaoui and McCluskie, Kerryn and Huisman, Gjalt and Silverman, Adam P},
  title = {Oral enzyme therapy for maple syrup urine disease ( MSUD ) suppresses plasma leucine levels in intermediate MSUD mice and healthy nonhuman primates},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2023},
  doi = {10.1002/jimd.12662}
}
Kostenlos starten →